References
1. Meena JP, Kumar Gupta A, Tanwar P, Ram Jat K, Mohan Pandey R, Seth R. Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review. Pediatr Blood Cancer . 2021;68(6):e29005. doi:10.1002/pbc.29005
2. Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr Blood Cancer . 2021;68(3):e28843. doi:10.1002/pbc.28843
3. Schmidt KLJ, Dautzenberg NMM, Hoogerbrugge PM, et al. Immune Response following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer Patients. Cancers (Basel) . 2023;15(9):2562. doi:10.3390/cancers15092562
4. Lehrnbecher T, Sack U, Speckmann C, et al. Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer.Clin Infect Dis . 2023;76(3):e510-e513. doi:10.1093/cid/ciac570
5. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell . 2021;39(8):1091-1098.e2. doi:10.1016/j.ccell.2021.06.009
6. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell . 2021;39(8):1081-1090.e2. doi:10.1016/j.ccell.2021.06.002
7. Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients.medRxiv . Published online April 7, 2021:2021.04.06.21254949. doi:10.1101/2021.04.06.21254949
8. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.JAMA . 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489
9. Hall VG, Ferreira VH, Ku T, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med . 2021;385(13):1244-1246. doi:10.1056/NEJMc2111462
10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med . 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
11. Sewell HF, Agius RM, Kendrick D, Stewart M. Covid-19 vaccines: delivering protective immunity. BMJ . 2020;371:m4838. doi:10.1136/bmj.m4838
12. Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. Clin Exp Immunol . 1976;24(1):54-62.